{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T18:04:04Z","timestamp":1780509844793,"version":"3.54.1"},"reference-count":25,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Sex Transm Infect"],"accepted":{"date-parts":[[2026,5,19]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatitis C virus (HCV) coinfection is a significant comorbidity and public health concern among people living with HIV (PLWH). This study aims to estimate HCV seroprevalence among PLWH in Istanbul, T\u00fcrkiye, and compare it with the HIV-negative control group and assess age-related patterns in PLWH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We performed a multicentre cross-sectional study including patients from nine distinct hospitals representing diverse districts of Istanbul between January 2022 and October 2025. Data were retrieved from the central laboratory system serving this hospital network. Anti-HCV was tested by third-generation electrochemiluminescence immunoassay (Elecsys Anti-HCV II, Roche). A total of 3361 PLWH and 3361 age-comparable and sex-comparable HIV-negative controls were included. Between-group differences were assessed with Fisher\u2019s exact test; within PLWH, age-group differences and trends were evaluated with \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      and linear-by-linear association tests.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>HCV seroprevalence was 0.71% among PLWH (24\/3361) and 0.39% in the control group (13\/3361), with no significant between-group difference (p=0.098). When PLWH were compared with HIV-negative controls, the odds of HCV seropositivity were not significantly increased (OR 1.85; 95% CI 0.94 to 3.70). Among PLWH, HCV seropositivity differed by age group (p=0.007) and increased with age (p&lt;0.001), with no seropositive cases in individuals younger than 30 years and the highest prevalence in those older than 70 years. Genotyping was available for eight PLWH; genotype 3 predominated (5\/8, 62.5%), followed by genotype 1 (3\/8, 37.5%; including subtypes 1a and 1b).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HCV seroprevalence was low among PLWH in T\u00fcrkiye and did not differ significantly from age-comparable and sex-comparable HIV-negative controls. The strong age gradient indicates that infections are concentrated in older cohorts and supports age-based screening for public health purposes in low-endemic settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/sextrans-2026-056936","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:20:50Z","timestamp":1780507250000},"page":"sextrans-2026-056936","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Low HCV seroprevalence among PLWH: a large cross-sectional study of 6722 individuals"],"prefix":"10.1136","author":[{"given":"Selim","family":"Merdan","sequence":"first","affiliation":[{"name":"Flow Cytometry Laboratory, \u00dcmraniye Training and Research Hospital, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8156-6633","authenticated-orcid":false,"given":"Abdurrahman","family":"Sarm\u0131\u015f","sequence":"additional","affiliation":[{"name":"Department of Microbiology Laboratory, G\u00f6ztepe Prof. Dr. S\u00fcleyman Yal\u00e7\u0131n City Hospital, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7275-8724","authenticated-orcid":false,"given":"Okan","family":"Aydo\u011fan","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Istanbul Medipol University School of Medicine, Istanbul, T\u00fcrkiye"},{"name":"Research Institute for Health Sciences and Technologies (SABITA), Istanbul Medipol University, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9551-1473","authenticated-orcid":false,"given":"Ya\u011fmur","family":"Ekeno\u011flu-Merdan","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Biruni University Faculty of Medicine, Istanbul, T\u00fcrkiye"},{"name":"Biruni Research Center (B@MER), Biruni University, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"2026060310203191000_sextrans-2026-056936v1.1","doi-asserted-by":"crossref","first-page":"101596","DOI":"10.1016\/j.clinre.2020.101596","article-title":"Epidemiology of hepatitis C virus infection","volume":"45","author":"Roudot-Thoraval","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2026060310203191000_sextrans-2026-056936v1.2","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.01331-22","article-title":"Diagnostic Performance of the HCV Core Antigen Test To Identify Hepatitis C in HIV-Infected Patients: a Systematic Review and Meta-Analysis","volume":"61","author":"Sep\u00falveda-Crespo","year":"2023","journal-title":"J Clin Microbiol"},{"key":"2026060310203191000_sextrans-2026-056936v1.3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.36519\/kd.2023.4473","article-title":"HBV and HCV Coinfection in Patients Living with HIV","volume":"36","author":"Tekin","year":"2023","journal-title":"Klimik Derg"},{"key":"2026060310203191000_sextrans-2026-056936v1.4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/jmv.24353","article-title":"Hepatitis C virus increases the risk of kidney disease among HIV-positive patients: Systematic review and meta-analysis","volume":"88","author":"Fabrizi","year":"2016","journal-title":"J Med Virol"},{"key":"2026060310203191000_sextrans-2026-056936v1.5","doi-asserted-by":"crossref","first-page":"333549231181348","DOI":"10.1177\/00333549231181348","article-title":"Hepatitis C Virus-HIV Coinfection in the United States Among People Who Inject Drugs: Data Needed for Ending Dual Epidemics","volume":"2023","author":"Moorman","year":"2023","journal-title":"Public Health Rep"},{"key":"2026060310203191000_sextrans-2026-056936v1.6","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ijid.2020.12.068","article-title":"Prevalence of HIV, HCV and HBV in Central Asia and the Caucasus: A systematic review","volume":"104","author":"Davlidova","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2026060310203191000_sextrans-2026-056936v1.7","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2352-3018(23)00267-9","article-title":"Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies","volume":"11","author":"Sacks-Davis","year":"2024","journal-title":"Lancet HIV"},{"key":"2026060310203191000_sextrans-2026-056936v1.8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.5152\/kd.2018.10","article-title":"Investigation of Hepatitis B and Hepatitis C Seroprevalence in HIV-Infected Patients","volume":"31","author":"\u0130nci","year":"2018","journal-title":"Klimik Dergisi"},{"key":"2026060310203191000_sextrans-2026-056936v1.9","article-title":"Prevalence of hepatitis C virus co-infection in adults living with HIV in Mexico: a cross-sectional, seroprevalence study in a nationally representative sample","volume":"41","author":"Belaunzar\u00e1n-Zamudio","year":"2025","journal-title":"Lancet Reg Health Am"},{"key":"2026060310203191000_sextrans-2026-056936v1.10","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"2026060310203191000_sextrans-2026-056936v1.11","unstructured":"von EE , Altman DG , Egger M , et al . The strobe reporting checklist. In: Harwood J , Albury C , de BJ , et al , eds. The EQUATOR network reporting guideline platform. The UK EQUATOR Centre, 2025."},{"key":"2026060310203191000_sextrans-2026-056936v1.12","unstructured":"2025. Available: https:\/\/hsgm.saglik.gov.tr\/depo\/birimler\/bulasici-hastaliklar-ve-erken-uyari-db\/Dokumanlar\/Istatistikler\/HIV_AIDS_Istatistikleri.pdf"},{"key":"2026060310203191000_sextrans-2026-056936v1.13","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/jvh.13554","article-title":"Injecting network structure determines the most efficient strategy to achieve Hepatitis C elimination in people who inject drugs","volume":"28","author":"Brown","year":"2021","journal-title":"J Viral Hepat"},{"key":"2026060310203191000_sextrans-2026-056936v1.14","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1016\/S2352-3018(20)30301-5","article-title":"HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study","volume":"8","author":"Smit","year":"2021","journal-title":"Lancet HIV"},{"key":"2026060310203191000_sextrans-2026-056936v1.15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3906\/sag-1308-3","article-title":"Mucocutaneous manifestations and the relationship to CD4 lymphocyte counts among Turkish HIV\/AIDS patients in Istanbul, Turkey","volume":"45","author":"Altunta\u015f Aydin","year":"2015","journal-title":"Turk J Med Sci"},{"key":"2026060310203191000_sextrans-2026-056936v1.16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4274\/vhd.galenos.2021.2021-1-4","article-title":"Hepatitis C Coinfection Among People Living with HIV in a University Hospital in \u0130stanbul","volume":"27","author":"Ergen","year":"2021","journal-title":"Vhd"},{"key":"2026060310203191000_sextrans-2026-056936v1.17","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001789"},{"key":"2026060310203191000_sextrans-2026-056936v1.18","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1007\/s10096-025-05199-1","article-title":"Burden of syphilis among people living with HIV: a large cross-sectional study from T\u00fcrkiye","volume":"44","author":"Merdan","year":"2025","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026060310203191000_sextrans-2026-056936v1.19","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1111\/liv.15981","article-title":"Prevalence of HCV infection in Europe in the DAA era: Review","volume":"44","author":"D\u2019Ambrosio","year":"2024","journal-title":"Liver Int"},{"key":"2026060310203191000_sextrans-2026-056936v1.20","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-9-201305070-00604"},{"key":"2026060310203191000_sextrans-2026-056936v1.21","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1111\/liv.15700","article-title":"Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort","volume":"43","author":"d\u2019Arminio Monforte","year":"2023","journal-title":"Liver Int"},{"key":"2026060310203191000_sextrans-2026-056936v1.22","doi-asserted-by":"crossref","first-page":"652","DOI":"10.5114\/aoms.2017.66022","article-title":"Intravenous drug use - an independent predictor for HCV genotypes 3 and 4 infection among HIV\/HCV co-infected patients","volume":"13","author":"Salemovic","year":"2017","journal-title":"Arch Med Sci"},{"key":"2026060310203191000_sextrans-2026-056936v1.23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4274\/vhd.galenos.2021.2020-12-6","article-title":"Frequency of HBV, HCV and HIV Infections and Determination of HCV Genotype Distribution in People who Inject Drugs","volume":"27","author":"Kara","year":"2021","journal-title":"Vhd"},{"key":"2026060310203191000_sextrans-2026-056936v1.24","unstructured":"T\u00fcrkiye Viral Hepatitis Prevention and Control Program (2025\u20132030) . Republic of t\u00fcrkiye ministry of health, general directorate of public health. isbn: 978-975-590-979-0. ministry of health publication no: 1364. 2025. Available: https:\/\/hsgm.saglik.gov.tr\/depo\/birimler\/bulasici-hastaliklar-ve-erken-uyari-db\/Dokumanlar\/Programlar\/Viral_hepaitit.pdf"},{"key":"2026060310203191000_sextrans-2026-056936v1.25","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijid.2017.07.001","article-title":"HCV mono-infected and HIV\/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?","volume":"62","author":"Bruno","year":"2017","journal-title":"Int J Infect Dis"}],"container-title":["Sexually Transmitted Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/sextrans-2026-056936","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:20:54Z","timestamp":1780507254000},"score":1,"resource":{"primary":{"URL":"https:\/\/sti.bmj.com\/lookup\/doi\/10.1136\/sextrans-2026-056936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":25,"alternative-id":["10.1136\/sextrans-2026-056936"],"URL":"https:\/\/doi.org\/10.1136\/sextrans-2026-056936","relation":{},"ISSN":["1368-4973","1472-3263"],"issn-type":[{"value":"1368-4973","type":"print"},{"value":"1472-3263","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]}}}